Skip to content

Study · Randomized controlled trial · n = 100 · 2023

2 results

Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study.

Tharoor H, Maran S, Chandan AK, Pari M, Rao S, Durairaj J

Pharmacology research & perspectives1 Apr 2023Cited by 10 (Europe PMC)

PMID36946070 (opens in a new tab)PMCIDPMC10031293 (opens in a new tab)DOI10.1002/prp2.1074 (opens in a new tab)PepBankPUB-36946070
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The antioxidant L-Carnosine is reported to improve negative and cognitive symptoms in Schizophrenia. A randomized double-blind placebo-controlled study was planned to study the effectiveness of adjuvant L-Carnosine therapy in patients with Schizophrenia. 100 eligible patients with predominant negative symptoms as measured by scale for assessment of negative symptoms (SANS total score ≥ 60) and Schizophrenia diagnosis (International Classification of Disorder-Tenth Edition, ICD-10) were recruited. They were randomly allocated to receive a fixed dose of either 400 mg L-Carnosine or identical placebo for 3 months and increased to 800 mg from 13th week till completion of study. Primary outcome measures assessed changes in SANS scores with L-Carnosine at 24 weeks compared to baseline, 4 and 12 weeks. Secondary outcome measures were done to assess the improvement in cognitive symptoms (executive function, attention, and memory) at 24 weeks using subtests of NIMHANS (National Institute for Mental Health and Neurosciences) cognitive battery. Side effects were assessed using adverse events reporting form. The attention scores (p = .023) showed significant differences in patients receiving 800 mg of L-Carnosine at the end of the study. There were no significant differences in negative symptoms in the two arms at study completion. L-Carnosine dosing of 800 mg may be a promising agent to enhance executive functions in Schizophrenia.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In schizophrenia, L‑carnosine did not significantly change negative symptoms versus placebo at study completion.

    In plain wordsIn schizophrenia, L‑carnosine did not significantly change negative symptoms versus placebo at study completion.

    Peptide
    L-carnosine
    Outcome
    No significant changeNegative symptoms
    Study

    n = 100

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    400 mg for 3 months, then 800 mg from week 13 · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in negative symptoms in the two arms at study completion.
    3 context sentences
    Summary · context
    Primary outcome measures assessed changes in SANS scores with L-Carnosine at 24 weeks compared to baseline, 4 and 12 weeks.
    Summary · context
    A randomized double-blind placebo-controlled study was planned to study the effectiveness of adjuvant L-Carnosine therapy in patients with Schizophrenia.
    Summary · context
    They were randomly allocated to receive a fixed dose of either 400 mg L-Carnosine or identical placebo for 3 months and increased to 800 mg from 13th week till completion of study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In schizophrenia, attention scores differed significantly with L‑carnosine versus placebo at study completion; the result sentence does not specify direction.

    In plain wordsIn schizophrenia, attention scores differed with L‑carnosine versus placebo at study completion; the result sentence does not specify direction.

    Peptide
    L-carnosine
    Outcome
    Direction not reportedAttention score
    Study

    n = 100

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    400 mg for 3 months, then 800 mg from week 13 · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The attention scores (p = .023) showed significant differences in patients receiving 800 mg of L-Carnosine at the end of the study.
    3 context sentences
    Summary · context
    Secondary outcome measures were done to assess the improvement in cognitive symptoms (executive function, attention, and memory) at 24 weeks using subtests of NIMHANS (National Institute for Mental Health and Neurosciences) cognitive battery.
    Summary · context
    A randomized double-blind placebo-controlled study was planned to study the effectiveness of adjuvant L-Carnosine therapy in patients with Schizophrenia.
    Summary · context
    They were randomly allocated to receive a fixed dose of either 400 mg L-Carnosine or identical placebo for 3 months and increased to 800 mg from 13th week till completion of study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.